| This week's sponsor is Premier Research. | |  | Rare Cancer Drug Research: What to Know Going In
Rare cancer drug research requires oncology and rare disease expertise and careful attention to trial design and regulatory demands. Get started with our white paper. Premier Research. It's what we do. Best. |
Today's Rundown | Publisher’s Note: In preparation for the new GDPR taking effect this month, we would like to reconfirm your subscription to our newsletter(s). Please click this link to reconfirm your subscription. For more information about GDPR, please visit this page. | |
|
Featured Story | | | Wednesday, May 16, 2018 Eleven Biotherapeutics is changing its name to Sesen Bio. The change comes 20 months after the then-flailing biotech merged with Viventia Bio and refocused on oncology. |
|
|
Top Stories Wednesday, May 16, 2018 EIP Pharma is enrolling a phase 2b trial of neflamapimod, a p38 MAP kinase alpha inhibitor that targets synaptic dysfunction rather than the suspected cause of it, such as amyloid buildup. Wednesday, May 16, 2018 Drug discovery startup FogPharma raised $66 million in series B financing as it looks to bring its first product to the clinic by the end of next year. The startup was established in 2016 by Harvard professor and entrepreneur Gregory Verdine, whose lab invented cell-penetrating miniproteins. Monday, May 14, 2018 For children diagnosed with rare diseases, traditional drug development timelines are not good enough. Collaborative partnerships are imperative to accelerate those timelines and expedite time to market for rare disease therapies. Wednesday, May 16, 2018 Trade group BioIndustry Association (BIA) has detailed its vision for unlocking capital to support the growth of British startups. The BIA wants the government to “democratize” biotech investing by eliminating perceived barriers to more widespread participation in the sector. Wednesday, May 16, 2018 Known as Panacea Pharmaceuticals until earlier this year, the renamed Sensei Biotherapeutics has appointed John Celebi as its new president and CEO as the company begins building clinical data on its lead cancer vaccine. Wednesday, May 16, 2018 Roivant has recruited a pair of Pfizer veterans: Salomon Azoulay will serve as chief medical officer, while Adele Gulfo joins as chief of commercial development. Wednesday, May 16, 2018 AstraZeneca is partnering with Emulate to incorporate organ-on-a-chip technology into the pharma giant’s R&D program with the aim of accelerating development of the technology within the company. Wednesday, May 16, 2018 Two people signed Novartis' infamous contract with Michael Cohen, and now they've both left. One was ex-CEO Joe Jimenez, who has his own take on the $1.2 million contract that landed Novartis in its biggest scandal yet. The other? General Counsel Felix Ehrat, who took "personal responsibility" and quit as of June 1. | This week's sponsor is Eurofins Advinus. | |  | |
Resources Sponsored by: Seton Hall Law 4-day interactive educational program trusted by multi-national companies as part of their compliance training for employees. Explore legal, regulatory and ethical issues faced by pharmaceutical, biotech and medical device manufacturers operating globally. Visit event homepage for session topics. Sponsored by: USDM Life Sciences What are the biggest trends in life sciences this year? Presented by: Patheon There are many parenteral dosage forms from which the pharmaceutical scientist can choose to develop their drug product. In this article, the author discusses the choices available and strategies which can be employed at the different stages of development. Sponsored by: Veeva Systems Explore a new model for events management, and learn how to deliver more value. Sponsored by: Veeva Systems To deliver value to key opinion leaders, medical affairs needs to tailor their engagement with deeper analytics and insights. Sponsored by: Veeva Systems Learn how leading companies, from the world’s top pharma to emerging biotechs, are empowering their medical affairs teams. Sponsored by: Veeva Systems Learn how to reduce change management burden, keep systems current, and maintain compliance by applying a risk-based approach to change management of GxP systems. Sponsored by: Veeva Systems UCB took a more holistic approach to managing regulatory processes. Read how their efforts are paying off. Sponsored by: Veeva Systems Find out how to eliminate regulatory’s tracking spreadsheets for good. Sponsored by: Veeva Systems Learn how cloud-enabled solutions provide real-time insights and actionable analytics to improve clinical trial safety and performance in this short presentation. Sponsored by: Docusign Life science companies are experiencing a significant transformation in how they bring new products to market. | 
